🇺🇸 FDA
Patent

US 10980889

C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

granted A61KA61K31/436A61K31/519

Quick answer

US patent 10980889 (C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors) held by Revolution Medicines, Inc. expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Revolution Medicines, Inc.
Grant date
Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/436, A61K31/519, A61K31/553, A61K47/545